ReviewWorld journal of hepatology2015
Markers of bacterial translocation in end-stage liver disease.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.The American journal of tropical medicine and hygiene · 2018Trial
- Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study.Gut and liver · 2017Trial
- Admission Plasma Lipopolysaccharide-binding protein, Procalcitonin, and Lactate for Early Identification of Nosocomial Infection in Cirrhotic Patients With Upper Gastrointestinal Bleeding: A Retrospective Analysis.The Kaohsiung journal of medical sciences · 2026Article
- DRD2 Deficiency Underlies Pituitary Adenoma Dependent on Escherichia coli Translocation from the Gut.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Gut dysbiosis in oncology: a risk factor for immunoresistance.Cell research · 2026Review
- Risk factors for bacterial translocation after loop ileostomy closure in patients with colorectal cancer.International journal of colorectal disease · 2025Article
- Liver as a key organ for systemic antimicrobial defense.Hepatology communications · 2025Review
- Interaction between haploinsufficiency of PTPN2 and patient microbiome promotes autoimmune arthritis in mice.Journal of autoimmunity · 2025Article
- Gut microbiota dysbiosis and associated immune response in systemic lupus erythematosus: impact of disease and treatment.Gut pathogens · 2025Article
- Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.World journal of hepatology · 2024Article
- Evaluation ofMicroorganisms · 2023Article
- Zonulin, a marker of gut permeability, is associated with mortality in a cohort of hospitalised peruvian COVID-19 patients.Frontiers in cellular and infection microbiology · 2022Article
- Update on blood-based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience.JGH open : an open access journal of gastroenterology and hepatology · 2021Review
- Article
- Identification of Aberrantly Methylated Differentially CpG Sites in Hepatocellular Carcinoma and Their Association With Patient Survival.Frontiers in oncology · 2020Article
- Neurocognitive impairment is worse in HIV/HCV-coinfected individuals with liver dysfunction.Journal of neurovirology · 2019Article
- Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression.Cells · 2019Review
- Effect of broad-spectrum antibiotics on bacterial translocation in burned or septic rats.Chinese medical journal · 2019Article
- Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.Digestive diseases and sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial translocation (BT) refers to the passage of viable bacteria or bacterial products from the intestinal lumen, through the intestinal epithelium, into the systemic circulation and extraintestinal locations. The three principal mechanisms that are thought to be involved in BT include bacterial overgrowth, disruption of the gut mucosal barrier and an impaired host defence. BT is commonly observed in liver cirrhosis and has been shown to play an important role in the pathogenesis of the complications of end stage liver disease, including infections as well as hepatic encephalopathy and hepatorenal syndrome. Due to the importance of BT in the natural history of cirrhosis, there is intense interest for the discovery of biomarkers of BT. To date, several such candidates have been proposed, which include bacterial DNA, soluble CD14, lipopolysaccharides endotoxin, lipopolysaccharide-binding protein, calprotectin and procalcitonin. Studies on the association of these markers with BT have demonstrated not only promising data but, oftentimes, contradictory results. As a consequence, currently, there is no optimal marker that may be used in clinical practice as a surrogate for the presence of BT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.